Sumitomo Mitsui DS Asset Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.29M Buy
19,126
+312
+2% +$77.8K 0.03% 346
2025
Q4
$4.53M Buy
18,814
+647
+4% +$165K 0.04% 338
2025
Q3
$4.97M Sell
18,167
-48
-0.3% -$13.1K 0.04% 317
2025
Q2
$4.7M Buy
18,215
+426
+2% +$102K 0.04% 316
2025
Q1
$3.98M Buy
17,789
+1,968
+12% +$459K 0.04% 339
2024
Q4
$3.62M Buy
15,821
+273
+2% +$65.7K 0.04% 350
2024
Q3
$3.8M Buy
15,548
+313
+2% +$69.9K 0.04% 338
2024
Q2
$2.92M Buy
15,235
+305
+2% +$61.9K 0.03% 369
2024
Q1
$2.96M Buy
14,930
+1,877
+14% +$344K 0.04% 361
2023
Q4
$2.25M Buy
13,053
+185
+1% +$28.4K 0.03% 424
2023
Q3
$1.9M Buy
12,868
+48
+0.4% +$8.68K 0.03% 412
2023
Q2
$2.8M Buy
12,820
+1,279
+11% +$285K 0.04% 331
2023
Q1
$2.53M Buy
11,541
+147
+1% +$31.9K 0.05% 322
2022
Q4
$2.37M Buy
11,394
+914
+9% +$201K 0.05% 318
2022
Q3
$2.29M Buy
10,480
+650
+7% +$148K 0.05% 301
2022
Q2
$2.06M Buy
9,830
+747
+8% +$159K 0.05% 305
2022
Q1
$2.2M Buy
9,083
+24
+0.3% +$5.8K 0.05% 316
2021
Q4
$2.36M Sell
9,059
-18
-0.2% -$4.67K 0.05% 330
2021
Q3
$2.39M Buy
9,077
+311
+4% +$85K 0.06% 291
2021
Q2
$2.16M Hold
8,766
0.05% 305
2021
Q1
$1.7M Hold
8,766
0.04% 353
2020
Q4
$1.86M Sell
8,766
-84
-0.9% -$16.7K 0.05% 313
2020
Q3
$1.52M Sell
8,850
-1,001
-10% -$185K 0.05% 318
2020
Q2
$1.89M Sell
9,851
-344
-3% -$56.3K 0.07% 235
2020
Q1
$1.5M Sell
10,195
-218
-2% -$34.7K 0.06% 255
2019
Q4
$1.61M Buy
10,413
+1,523
+17% +$220K 0.05% 302
2019
Q3
$1.2M Buy
8,890
+1,449
+19% +$190K 0.04% 357
2019
Q2
$908K Sell
7,441
-19,813
-73% -$2.19M 0.04% 395
2019
Q1
$2.83M Sell
27,254
-1,771
-6% -$183K 0.05% 289
2018
Q4
$3.31M Sell
29,025
-2,867
-9% -$307K 0.06% 228
2018
Q3
$3.68M Sell
31,892
-4,074
-11% -$446K 0.06% 239
2018
Q2
$3.73M Sell
35,966
-504
-1% -$51K 0.06% 246
2018
Q1
$3.59M Buy
36,470
+1,689
+5% +$160K 0.05% 261
2017
Q4
$2.94M Buy
34,781
+24,255
+230% +$2M 0.04% 305
2017
Q3
$810K Sell
10,526
-154
-1% -$11.8K 0.01% 543
2017
Q2
$831K Sell
10,680
-51
-0.5% -$3.65K 0.01% 534
2017
Q1
$772K Buy
10,731
+872
+9% +$60.3K 0.01% 568
2016
Q4
$611K Sell
9,859
-93
-0.9% -$5.7K 0.01% 579
2016
Q3
$644K Hold
9,952
0.01% 560
2016
Q2
$629K Sell
9,952
-13,746
-58% -$810K 0.02% 528
2016
Q1
$1.37M Sell
23,698
-150
-0.6% -$8.49K 0.04% 327
2015
Q4
$1.28M Sell
23,848
-1,200
-5% -$67.6K 0.04% 327
2015
Q3
$1.28M Hold
25,048
0.04% 340
2015
Q2
$1.41M Sell
25,048
-820
-3% -$51.8K 0.04% 348
2015
Q1
$1.86M Buy
25,868
+14,164
+121% +$920K 0.06% 291
2014
Q4
$656K Sell
11,704
-971
-8% -$50.7K 0.02% 583
2014
Q3
$624K Sell
12,675
-810
-6% -$41.3K 0.02% 599
2014
Q2
$682K Buy
13,485
+9
+0.1% +$446 0.02% 611
2014
Q1
$602K Sell
13,476
-2,763
-17% -$124K 0.02% 652
2013
Q4
$764K Sell
16,239
-203
-1% -$10.3K 0.02% 598
2013
Q3
$868K Sell
16,442
-1,989
-11% -$96.5K 0.02% 540
2013
Q2
$831K Buy
+18,431
New +$874K 0.02% 542

Other funds holding RMD

Sumitomo Mitsui DS Asset Management's RMD Position: Q1 2026 in Review

Sumitomo Mitsui DS Asset Management increased its ResMed (RMD) stake by 1.7% in Q1 2026, buying an estimated $77.8K and bringing the position to 19,126 shares worth $4.29M. The position accounts for 0.03% of the portfolio, ranked #346.

Sumitomo Mitsui DS Asset Management first reported a position in RMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.97M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Sumitomo Mitsui DS Asset Management held 19,126 shares of ResMed worth $4.29M as of Q1 2026.
  • Sumitomo Mitsui DS Asset Management bought 312 ResMed shares in Q1 2026, an estimated $77.8K.
  • ResMed made up 0.03% of Sumitomo Mitsui DS Asset Management's portfolio in Q1 2026, its #346 holding.
  • Sumitomo Mitsui DS Asset Management first reported a position in ResMed in Q2 2013 and has held it in 52 quarters since.
  • Sumitomo Mitsui DS Asset Management's ResMed position peaked at $4.97M in Q3 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.